S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Scilex Holding Company Common Stock

SCLX XNAS
$7.82 -0.23 (-2.86%) ▼ 15-min delayed
Open
$8.20
High
$8.62
Low
$7.67
Volume
112.5K
Market Cap
$55.00M

About Scilex Holding Company Common Stock

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 34 Website →

Key Financials

Period Revenue Net Income EPS
TTM 2025 $30.25M $-362,253,000 $-36.48
FY 2025 $30.25M $-362,253,000 $-36.48
Q3 2025 $10.56M $-257,820,000 $-22.17
Q1 2025 $5.00M $-26,080,000 $-2.26

Related Market News

No specific coverage for SCLX yet. Check out our latest market news or earnings calendar.

Get SCLX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Scilex Holding Company Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.